Biološke učinkovine pri Alzheimerjevi bolezni
Biopharmaceuticals for Alzheimer’s disease

slovenian

2024

volume 75, issue 2

aducanumab   Alzheimer’s disease   biological drugs   lecanemab   monoclonal antibodies

Slovensko farmacevtsko društvo
(Obvezni izvod spletne publikacije)

According to the beta amyloid hypothesis the main cause of Alzheimer’s disease is accumulation of amyloid plaques in the brain tissue and subsequent intracellular deposits of tau protein. In the development of biopharmaceuticals for treatment of Alzheimer’s disease, researchers focused mainly on targets related to the formation of amyloid plaques, neurofibrillary tangles and on targets affecting the activity of glia cells and the inflammatory response in the central nervous system. Monoclonal antibodies directed against components of the amyloid pathway have achieved the most success thus far. Aducanumab and lekanemab have recently obtained marketing authorization in the USA via the expedited clearance pathway based on the achievement of a surrogate endpoint. The modest clinical effect in the prevention of cognitive decline, despite the effective removal of amyloid plaques, confirms that many other factors are involved in the mechanism. This will need to be considered in further efforts to prevent neurodegeneration and develop disease modifying treatment.

24.10.2024